Clinical Trials Logo

Adult Mixed Glioma clinical trials

View clinical trials related to Adult Mixed Glioma.

Filter by:

NCT ID: NCT01024907 Completed - Clinical trials for Recurrent Adult Brain Tumor

Proton Beam Radiation Therapy in Treating Patients With Low Grade Gliomas

Start date: December 17, 2009
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: Specialized radiation therapy, such as proton beam radiation therapy, that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. PURPOSE: This phase I/II trial is studying the best way to give proton beam radiation therapy and to see how well it works in treating patients with low grade gliomas.

NCT ID: NCT00823459 Completed - Adult Mixed Glioma Clinical Trials

Everolimus in Treating Patients With Recurrent Low-Grade Glioma

Start date: January 23, 2009
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well everolimus works in treating patients with recurrent low-grade glioma. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor.

NCT ID: NCT00650923 Completed - Adult Glioblastoma Clinical Trials

Aflibercept, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme, Gliosarcoma, or Other Malignant Glioma

Start date: July 2008
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of aflibercept when given together with radiation therapy and temozolomide in treating patients with newly diagnosed or recurrent glioblastoma multiforme, gliosarcoma, or other malignant glioma. Aflibercept may stop the growth of tumor cells by blocking blood flow to the tumor. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving aflibercept together with radiation therapy and temozolomide may kill more tumor cells.

NCT ID: NCT00499473 Completed - Adult Glioblastoma Clinical Trials

Sunitinib in Treating Patients With Recurrent Malignant Gliomas

Start date: June 2007
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well sunitinib works in treating patients with recurrent malignant gliomas. Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

NCT ID: NCT00492089 Completed - Malignant Neoplasm Clinical Trials

Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer

Start date: June 2007
Phase: Phase 2
Study type: Interventional

Bevacizumab may reduce CNS side effects caused by radiation therapy. This randomized phase II trial is studying how well bevacizumab works in reducing CNS side effects in patients who have undergone radiation therapy to the brain for primary brain tumor, meningioma, or head and neck cancer.

NCT ID: NCT00112736 Completed - Adult Glioblastoma Clinical Trials

Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma

Start date: April 2005
Phase: Phase 1/Phase 2
Study type: Interventional

Erlotinib and temsirolimus and may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This phase I/II trial is studying the side effects and best dose of temsirolimus when given together with erlotinib and to see how well they work in treating patients with recurrent malignant glioma.

NCT ID: NCT00085540 Completed - Adult Gliosarcoma Clinical Trials

FR901228 in Treating Patients With Recurrent High-Grade Gliomas

Start date: January 2005
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial is studying the side effects and best dose of FR901228 and to see how well it works in treating patients with recurrent high-grade gliomas. FR901228 may stop the growth of tumor cells by blocking the enzymes necessary for their growth

NCT ID: NCT00049127 Completed - Clinical trials for Adult Anaplastic Oligodendroglioma

Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor

Start date: June 2003
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial is studying the side effects and best dose of imatinib mesylate and to see how well it works in treating patients with a recurrent brain tumor that has not responded to previous surgery and radiation therapy. Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth.

NCT ID: NCT00030498 Completed - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction

Start date: December 2001
Phase: Phase 1
Study type: Interventional

Phase I trial to study the effectiveness of erlotinib in treating patients who have metastatic or unresectable solid tumors and liver or kidney dysfunction. Biological therapies such as erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor